FILE PHOTO: A logo is pictured on the Ibex building of Lonza, where the Moderna mRNA coronavirus disease (COVID-19) vaccine will be produced, in Visp, Switzerland, September 29, 2020. REUTERS/Denis Balibouse
ZURICH (Reuters) - Three new Lonza production lines that manufacture ingredients for Moderna's COVID-19 vaccine are due to be producing at capacity by the end of June, Chief Executive Pierre-Alain Ruffieux said on Thursday in an interview.
Ruffieux spoke to Reuters after Lonza extended a deal with Moderna to build three additional lines, doubling existing capacity in 2022.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
